Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments.
In less than 3 years, Nicoya has grown rapidly from 14 to 70+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions.
Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines.